Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations

European Neurology

Volumn 50, Issue 1, 2003, Pages 10-15

  Hengstman, G J D ^a   Van Den Hoogen, F H J ^a   Barrera, P ^a   Netea, M G ^a   Pieterse, A ^a   Van De Putte, L B A ^a   Van Engelen, B G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dermatomyositis; Myositis; Polymyositis; Tumor necrosis factor

Indexed keywords

GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CYTOKINE PRODUCTION; DERMATOMYOSITIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELECTROMYOGRAPHY; FEMALE; FOLLOW UP; HUMAN; POLYMYOSITIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; BIOPSY; CREATINE KINASE; CYTOKINES; DERMATOMYOSITIS; DRUG ADMINISTRATION SCHEDULE; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; ISOMETRIC CONTRACTION; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038646387     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070852     Document Type: Article

References (20)

1. Dalakas MC: Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.
2. Amato AA, Barohn RJ: Idiopathic inflammatory myopathies. Neurol Clin 1997;15:615-648.
3. Catoggio LJ: Inflammatory muscle disease: Management; in Klippel JH, Dieppe PA (ed): Rheumatology. London, Mosby, 1998, pp 7.15.1-7.15.6.
4. Lindberg C, Oldfors A, Tarkowski A: Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol 1995;41:421-426.
5. Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 1995;63:9-16.
6. Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342-347.
7. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997;40:865-874.
8. Lundberg IE, Nyberg P: New developments in the role of cytokines and chemokines in inflammatory myopathies. Curr Opin Rheumatol 1998;10:521-529.
9. De Bleecker J, Meire V, Declercq W, Van Aken E: Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 1999;9:239-246.
10. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;136:1433-1450.
11. Keystone EC: The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999;26(suppl 57):22-28.
12. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-1563.
13. Moreland LW: Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999;26(suppl 57):7-15.
14. Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999;5:119-133.
15. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-347.
16. Van Crevel R, Van der Ven-Jongekrijg J, Netea MG, De Lange W, Kullberg WJ, Van der Meer JW: Disease-specific ex vivo stimulation of whole blood for cytokine production: Applications in the study of tuberculosis. J Immunol Methods 1999;222:145-153.
17. Drenth JP, Van Uum SH, Van Deuren M, Pesman GJ, Van der Ven-Jongekrijg J, Van der Meer JW: Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1beta production. J Appl Physiol 1995;79:1497-1503.
18. Personius KE, Pandya S, King WM, Tawil R, McDermott MP: Facioscapulohumeral dystrophy natural history study: Standardization of testing procedures and reliability of measurements. The FSHDY group. Phys Ther 1994;74:253-263.
19. The national isometric muscle strength (NIMS) database consortium: Muscular weakness assessment: Use of normal isometric strength data. Arch Phys Med Rehabil 1996;77:1251-1255.
20. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M: Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336-348.